Cancer

Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045

- New Composition of Matter Intellectual Property ("IP") Filing Centered on First-in-Class, Fully Synthetically Manufactured Halneuron®-- New Synthetic Process to…

4 days ago

Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT

sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025First Phase…

4 days ago

PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)

Company to Discuss Proposed Amendment to Phase 3 VERSATILE-003 Trial Enabling Potential Accelerated Approval PathwayPRINCETON, N.J., Dec. 02, 2025 (GLOBE…

4 days ago

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now

AUSTIN, Texas, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioMedWire: Chronic conditions and rare diseases in the aging population present an…

4 days ago

BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization

SHERIDAN, Wyo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BGLC” or the “Company”), an emerging provider of…

4 days ago

First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin

SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company committed to realizing the…

4 days ago

DoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its Portfolio

DNA-based Colorectal Cancer Screening as a Home TestBERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed…

4 days ago

Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer

Positive feedback reinforces Silexion’s trajectory toward its planned Phase 2/3 trial initiation in Q2 2026 Company plans to complete regulatory…

4 days ago

Oncotelic and Sapu Nano Unveils Broad-Applicability Deciparticle™ Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide Drugs

AGOURA HILLS, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano, a…

4 days ago

Three Trailblazing Women in Health Care Honoured with the Medal of the Member of the National Assembly

Three Trailblazing Women in Health Care Honoured with the Medal of the Member of the National Assembly Jennifer Maccarone, MNA…

4 days ago